Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Carruthers A, Kiene K, Carruthers J (1996) Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34(5): 788–797
Tintner R, Jankovic J (2001) Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep 1(4): 337–345
Smith ME, Ford CN (2000) Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 126(4): 533–535
Siatkowski RM et al (1993) Serum antibody production to botulinum A toxin. Ophthalmology 100(12): 1861–1866
Elan Pharmaceutical Inc (2000) Myobloc package insert
Guttman C (2002) Botulinum toxin type B option for wrinkles, sweating. Dermatology Times
Foster JA et al (1996) The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 103(4): 618–622
Scott AB, Rosenbaum A, Collins C (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12(12): 924–927
Naumann M, Lowe NJ (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised parallel group double blind placebo controlled trial. BMJ 323(7313): 596–599
Borodic GE, Cheney M, McKenna M (1992) Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 90(6): 972–979
Lowe NJ, Maxwell A, Harper H (1996) Botulinum A exotoxin for glabellar folds: a double-blind placebocontrolled study with an electromyographic injection technique. J Am Acad Dermatol 35(4): 569–572
Blitzer A et al (1997) The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 123(4): 389–392
Fodor P, Nicanor GI, Hengst TC (1996) Endoscopically assisted plastic surgery. Mosby, St Louis
Allergan Pharmaceuticals (2002) Botox Cosmetic (botulinum toxin type A). Prescribing information
Carruthers A, Carruthers J (1994) Botulinum toxin used in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 577–595
Dysport Cbotulinum type A toxin-haemagglutinin complex: patient information leaflet
Elan Pharmaceuticals (2004) Myobloc: Cosmetic use
Sadick NS, Faacs (2002) Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 28(9): 817–821
Sadick NS (2003) Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2400 and 3000 U for the treatment of glabellar wrinkles. Dermatol Surg 29(5): 501–507
Spencer JM, Gordon M, Goldberg DJ (2002) Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther 4(1): 19–23
Ramirez AL, Reeck J, Maas CS (2002) Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 126(5): 459–467
Alster TSL, Lupton J R (2003) Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 29(5): 516–518
Lowe NJ et al (2002) Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4(1): 15–18
Flynn TC, Clark RE (2003) 2nd Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29(5): 519–522
Baumann L et al (2003) A double-blinded randomized placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow’s feet: a double-blinded placebo-controlled trial. Dermatol Surg 29(5): 508–515
Matarasso SL (2003) Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 29(1): 7–13
Borodic G (1998) Myasthenic crisis after botulinum toxin Lancet 352(9143): 1832
Erbguth F et al (1993) Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome J Neurol Neurosurg Psychiatry 56(11): 1235–1236
ATC Draft (2001) Facial aesthetic enhancements: chemodenervation and tissue augmentation pp 76
Finn JC (2004) Botulinum toxin type A: fine-tuning treatment of facial nerve injury. J Drugs Dermatol 3(2): 133–137
Flynn TC, Carruthers, JA (2001) Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 27(8): 703–708
Carruthers J, Carruthers A (2001) BOTOX use in the mid and lower face and neck. Semin Cutan Med Surg 20(2): 85–92
Becker-Wegerich PM, Rauch L, Ruzicka T (2002) Botulinum toxin A: successful décolleté rejuvenation. Dermatol Surg 28(2): 168–171
Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3(4): 333–335
Lange DJ et al (1991) Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 14(7): 672–675
Girlanda P et al (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55(9): 844–845
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Burgess, C.M. (2005). Botulinum Toxin. In: Burgess, C.M. (eds) Cosmetic Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27333-6_5
Download citation
DOI: https://doi.org/10.1007/3-540-27333-6_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23064-9
Online ISBN: 978-3-540-27333-2
eBook Packages: MedicineMedicine (R0)